All still for play for in haemophilia gene therapy race
As durability continues to fog the future for Biomarin’s gene therapy, Pfizer and Sangamo keep up the pressure.
EHA 2020 – the sickle cell competition hots up
Behind Global Blood and Novartis, Bluebird leads a pack of biotechs wanting a slice of the sickle cell disease market.
EHA 2020 – Bluebird’s sickle cell plan takes shape, with a stark reminder
The plan to file Lentiglobin for sickle cell disease next year gets the green light, as a patient death is deemed unrelated to treatment.
Alexion goes in a new direction with $1.4bn Portola buy
Alexion’s move on the anticoagulant reversal specialist is not the most intuitive deal – but is 2020’s second biggest so far.
Akebia confirms its place in the anaemia race
Two successful pivotal trials with vadadustat put Akebia on track to file its novel anaemia pill by year end – hot on the heels of Fibrogen.
Setback lays bare Novo’s need in haemophilia
Novo Nordisk is in danger of being left behind in haemophilia, and new safety fears around its lead R&D project make this more likely. But could a setback prompt deal…
Rubius confirms the worst
The collapse of Rubius’s first attempt to demonstrate the worth of its red blood cell platform proves that this company should never have gone public.
Becton Dickinson out for blood with new partnership
There is a ready market for blood tests that do not involve putting a needle to a vein. Can a new partnership meet the demand?
Acceleron’s post-Reblozyl plan comes together
Sotatercept’s win in pulmonary arterial hypertension positions Acceleron for a battle against the leaders in this crowded space.
